Company Profile
Hangzhou Jinlan Pharm-Drugs Technology Co. Ltd.(JL Pharm) is an advanced pharmaceutical corporation with a laboratory of 1200 square meters in Nanjing city, and cooperative GMP production plants in Beljing, Jiangsu, Zhejiang, Jiangxi, Chengdrand Shandong.We can provide both CDMO technology research and development services, and a ful range of laboratory R&D and production services for raw materials and pharmaceutical intermediates to globapharmaceutical companies during which synthetic route research and development, process reearch and development and optimization, scale-up production, domestic and foreign drug registration, and industrial equipment selection, automatic control system and technical process packages.
Packaging & Shipping
Product Name: Rimegepant
Synonyms:
BMS 927711;BMS-927711;
4-(2,3-Dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)-1-piperidinecarboxylic acid (5S,6S,9R)-5-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-yl ester;
Rimegepant;
CS-2806;
BMS-927711(Rimegepant);
BMS 92771;RIMEGEPANT;
BMS-927711;
BMS927711;
BMS 92771
CAS: 1289023-67-1
MF: C28H28F2N6O3
MW: 534.56
EINECS:
Product Categories: API;1289023-67-1
Mol File: 1289023-67-1.mol
Rimegepant Chemical Properties
density 1.45±0.1 g/cm3(Predicted)
storage temp. Store at -20°C
solubility Soluble in DMSO
form A crystalline solid
pka 12.03±0.20(Predicted)
Rimegepant Usage And Synthesis
Description Rimegepant (Nurtec ODT)(FDA approved in February 2020) is an ODT available in a single strength of 75 mg for the acute treatment of migraine with or without aura in adults.No more than 75 mg should be taken in a 24-hour period. while there are no contraindications,concomitant administration with CYP3A4 inhibitors should be avoided.The most common adverse reaction is nausea, occurring in few patients (rimegepant PI, 2020). In clinical trials, a single 75-mg dose of rimegepant demonstrated superiority over placebo with regard to freedom from pain (21% in the rimegepant group vs.11% in the placebo group) and freedom from the most bothersome symptom (35% vs. 27%) at 2 hours post dose (Croop et al., 2019). Rimegepant is not approved for migraine prevention, although it is presently in late-stage clinical trials assessing it for that indication(NCT03732638,2020).
Uses Rimegepant is an oral calcitonin gene-related peptide (CGRP) receptor antagonist used for the treatment of migraine.
Rimegepant Preparation Products And Raw materials
Raw materials 1-Piperidinecarboxylic acid, 4-(2,3-dihydro-2-oxo-1H-imidazo[4,5-b]pyridin-1-yl)-, (5S,6S,9R)-5-azido-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-yl ester
Tag:Rimegepant(1289023-67-1) Related Product Information
Audited Supplier 
){kind=link}
){kind=link}